News

We were thrilled to launch our 'Truth Be Told' photographic exhibition roadshow last week, with Newcastle paving the way for more dates in other locations. Held at Newcastle Arts Centre on April 26 and 27, with a special preview on the evening of April 25, the exhibition showcased the challenges, and the hope and strength, shown by women living with secondary breast cancer through captivating photography originally shot by Jennifer Willis from Northern Ireland.

The Lancet is a peer-reviewed medical journal and is also one of the world's highest- impact academic journals. In addition to weekly publication of original research, it runs projects called Commissions.

In a first for the charity, we are working with the National Institute for Health and Care Excellence (NICE) as a stakeholder in the drug consultation process for a new treatment for secondary breast cancer called Elacestrant. Elacestrant is currently approved to treat people in the EU and USA living with oestrogen receptor-positive (HR+) HER2-negative (HER2-) secondary breast cancer with an ESR1 mutation, who experience disease progression after at least one line of hormone therapy.

The Make 2nds Count Patient Trials Advocate (PTA) service has so far supported 500 secondary breast cancer patients across the UK, marking a significant milestone and pivotal achievement in advancing patient access to clinical trials. The PTA service is the first of its kind in the UK, offering fresh hope to patients by connecting them with clinical trials that have the potential to improve outcomes and extend life.

Make 2nds Count is pleased to hear from the Scottish Medicines Consortium (SMC) that Talazoparib (Talzenna) has been approved to treat adults with BRCA1 or 2 mutated HER2-negative secondary breast cancer. The announcement is welcome news for many people in Scotland and their families as this is the first ever BRCA-targeted treatment for those living with locally advanced or secondary breast cancer.